You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: January 1, 2026

Drug Price Trends for NDC 00469-0687


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00469-0687

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
ASTAGRAF 5MG CAP,SA Astellas Pharma U.S., Inc. 00469-0687-73 30 459.22 15.30733 2021-09-30 - 2026-09-29 FSS
ASTAGRAF 5MG CAP,SA Astellas Pharma U.S., Inc. 00469-0687-73 30 483.97 16.13233 2022-01-01 - 2026-09-29 FSS
ASTAGRAF 5MG CAP,SA Astellas Pharma U.S., Inc. 00469-0687-73 30 523.66 17.45533 2023-01-01 - 2026-09-29 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 00469-0687

Last updated: July 28, 2025

Introduction

NDC 00469-0687 refers to a specific pharmaceutical product registered under the National Drug Code (NDC) system. While the precise drug name is not provided, the structure of this report centers on analyzing the market landscape, competitive positioning, pricing trends, and future projections based on general industry dynamics and available data.

Product Overview

The NDC 00469-0687 corresponds to a prescription medication uniquely identified within the US healthcare system. Its usage and demand depend on its therapeutic class, indications, formulation, and approval status. These factors directly influence its market trajectory and price behavior over time.

Market Dynamics

Therapeutic Area and Disease Landscape

Understanding the therapeutic domain is essential. For instance, if the drug targets chronic conditions such as rheumatoid arthritis or diabetes, ongoing demand and market stability tend to be high, especially given the prevalence rates. Conversely, drugs for rare diseases or niche indications typically see limited but stable markets, potentially affecting pricing strategies.

Regulatory Status and Patent Exclusivity

The drug’s patent status and regulatory approvals significantly impact market exclusivity and pricing power. If the product is under patent protection or has recent exclusivity extensions, manufacturers can maintain higher price points — often justified by R&D investments and limited competition. Loss of exclusivity can lead to increased competition, price erosion, and market sharing.

Competitive Landscape

Assessing competitors involves identifying similar products—either branded or generic—and their respective market shares, pricing strategies, and approval timelines. The entrance of biosimilars or generics post-patent expiry typically exerts downward pressure on prices.

Market Penetration and Adoption

Prescription volume trends, payer acceptance, insurance coverage, and formulary inclusion influence how widely the drug is adopted. Market penetration rates directly impact revenue projections and pricing strategies.

Supply Chain & Distribution

Manufacturing capacity, supply chain robustness, and distribution channels also influence market stability and pricing. Any disruptions or shortages tend to transiently inflate prices, whereas oversupply can drive prices downward.

Historical Pricing Trends

While specific data for NDC 00469-0687 are not publicly accessible here, general patterns in similar therapeutic classes suggest:

  • Initial Launch Prices: Typically high, reflecting R&D costs, patent protection, and market exclusivity.
  • Post-Patent Expiry: A gradual decline in price, often around 20-50%, due to generic competition.
  • Negotiated Payer Discounts: Commercial insurers and pharmacy benefit managers (PBMs) negotiate rebates and discounts, influencing the net price.

Pricing Considerations

  • List Price: Often used as a benchmark; however, net price post-discounts is more indicative of market reality.
  • Pricing Trends: Recent years have seen moderate to high price increases in specialty drugs, driven by innovation, biosimilar entry delays, and manufacturing complexities.

Price Projections and Future Outlook

Factors Influencing Future Prices

  • Patent Status & Market Exclusivity: If the patent is nearing expiration, price reductions are imminent unless extended via additional patents or exclusivity periods.
  • Market Competition: Entry of biosimilars or generics would likely reduce prices by 20-50% within 1-3 years post-patent expiry.
  • Regulatory Changes: Legislation encouraging biosimilar proliferation, such as the Biologics Price Competition and Innovation Act (BPCIA), could accelerate price declines.
  • Reimbursement Policies: Payer shifts towards value-based models may pressure manufacturers to justify pricing with clinical outcomes, potentially stabilizing or reducing prices.
  • Manufacturing & Supply Dynamics: Any manufacturing innovations or constraints affect availability and pricing stability.

Projected Price Trends (Next 3-5 Years)

  • If Patent Protected: Predicted stability or slight increases in list prices, aligning with inflation trends and investment recovery.
  • Post-Patent Expiry: Anticipate a gradual decrease in net prices, totaling 20-50% over 3 years, influenced by biosimilar market entry.
  • Market Penetration Strategies: Manufacturers may employ pricing strategies—such as introductory discounts or outcome-based pricing—to maintain market share.

Implications for Stakeholders

  • Pharmaceutical Companies: Strategic planning around patent protection, lifecycle management, and competitive positioning is crucial.
  • Payers and Insurers: Monitoring price trends and negotiating for rebates can optimize formulary management.
  • Healthcare Providers: Awareness of actual net costs informs prescribing decisions and cost-effective treatment planning.
  • Patients: Access and affordability hinge upon insurer policies, availability of generics/biosimilars, and manufacturer pricing strategies.

Key Challenges and Opportunities

  • Access: Ensuring patient access amidst price inflation in specialty markets.
  • Innovation: Investing in biosimilars and new formulations to promote competition.
  • Regulatory Environment: Navigating evolving policies that influence market entry and price controls.
  • Market Expansion: Exploring off-label uses or broader indications can stabilize demand and influence pricing.

Key Takeaways

  • The current market for NDC 00469-0687 is heavily influenced by patent status, competitive landscape, and therapeutic demand.
  • Historically high launch prices are typical, with significant reductions expected upon patent expiration.
  • Biosimilar and generic entry are primary drivers of future price declines, projected at 20-50% within 3 years post-patent expiry.
  • Market access strategies, payer negotiations, and regulatory developments will shape pricing stability and visibility.
  • Stakeholders should focus on lifecycle management and innovation to sustain profitability and ensure patient access.

FAQs

  1. What is the typical timeline for price declines after patent expiry?
    Price reductions of 20-50% commonly occur within 1-3 years post-patent expiration, influenced by biosimilar/generic market entry and competitive strategies.

  2. How does regulatory exclusivity impact pricing?
    Regulatory exclusivity prolongs patent protection, enabling manufacturers to maintain higher pricing without generic competition for a set period, typically 12-14 years for biologics.

  3. What factors could prevent significant price reductions?
    Factors include high manufacturing costs, complex delivery systems, limited biosimilar interest, or regulatory/legal barriers to biosimilar approval.

  4. How can manufacturers extend product lifecycle profitability?
    Strategies include obtaining additional patents, developing new formulations, expanding indications, or employing value-based pricing models.

  5. What role do payers and insurance companies play in pricing?
    Payers negotiate rebates, discounts, and formulary placements, directly affecting the net price paid and influencing overall market prices.


Sources:

  1. FDA’s Orange Book (for patent and exclusivity data).
  2. IQVIA data reports (for market size and pricing trends).
  3. Industry analysis reports (e.g., EvaluatePharma, GlobalData).
  4. Regulatory and legislative updates (US Congress and FDA guidelines).
  5. Peer-reviewed studies on biosimilar market dynamics.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.